Salisbury Eye Evaluation Research Articles

Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

To quantify the cost-utility ratio of the ranibizumab Port Delivery System (PDS; SUSVIMO) versus intravitreal ranibizumab injections for treating neovascular age-related macular degeneration (nAMD) based upon Archway Phase 3 Trial data. Cost-utility analysis. Archway Phase 3 Clinical Trial nAMD participants previously responsive to anti-VEGF therapy were randomized 3:2. Two hundred forty received PDS refills q 24 weeks and 162 received ranibizumab injections. Ophthalmic patient, time tradeoff utilities, direct medical and societal cost perspectives, 12-year, 1-year, and 5-year timelines, United States 2022 real dollars, and a 3% annual discount rate were employed. Utilities were adjusted for nAMD conversion in fellow eyes during the 12-year, mean participant life expectancy. Premature death associated with severe vision loss was integrated as per the population-based Salisbury Eye Evaluation Study. Quality-adjusted life-year (QALY) accruals, costs, and incremental and average cost-utility ratios in $/QALY (dollars expended per QALY gained). Versus no therapy, the 1-year PDS QALY gain was 0.0156 (6.8%) versus 0.0063 (0.82%) for intravitreal injections (P < 0.001), whereas the respective 12-year QALY gains were 1.714 (28%) and 1.639 (26.8%) (P= 0.99). One-year direct PDS ophthalmic costs totaled $21 825 with 2 ranibizumab fills, whereas ranibizumab injection therapy totaled $18 405 with 11.8 injections. The 1-year incremental PDS $/QALY versus injections was cost effective at $75 497/QALY. Five-year PDS therapy was not incrementally cost effective at $304 108/QALY, nor was the 12-year therapy at $761 646/QALY. Average 12-year cost-utility ratios were $78773/QALY for the PDS and $47 917/QALY for injection therapy. Adding-$476 442 12-year offsetting societal costs netted $314 521 to society per PDS participant versus $370 958 per participant for injection therapy. Ranibizumab PDS therapy was not incrementally cost effective versus ranibizumab injection therapy at 12 or 5 years but was at 1 year. Injection therapy had a more favorable 12-year average cost-utility ratio. Vision gain was the major determinant of participant value gain and was the same for both interventions. Both interventions were highly cost effective utilizing average cost-utility analysis with the societal cost perspective. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Autologous serum eye drops diluted with 0.5% methylcellulose and 0.9% saline solution: a clinical comparative study

Purpose: This clinical study compared autologous serum eye drops diluted with 0.5% methylcellulose and 0.9% saline solution. The subjective criteria for symptom improvement and the objective clinical criteria for response to therapy were evaluated. Methods: This longitudinal prospective study enrolled 23 patients (42 eyes) with persistent epithelial defects or severe dry eye disease refractory to conventional therapy who had been using autologous serum 20% prepared with methylcellulose for >6 months and started on autologous serum diluted in 0.9% saline solution. The control and intervention groups consisted of the same patients under alternate treatments. The subjective criteria for symptom relief were evaluated using the Salisbury Eye Evaluation Questionnaire. The objective clinical criteria were evaluated through a slit-lamp examination of the ocular surface, tear breakup time, corneal fluorescein staining, Schirmer’s test, rose Bengal test, and tear meniscus height. These criteria were evaluated before the diluent was changed and after 30, 90, and 180 days. Results: In total, 42 eyes were analyzed before and after 6 months using autologous serum diluted with 0.9% saline. No significant differences were found in the subjective criteria, tear breakup time, tear meniscus, corneal fluorescein staining, or rose Bengal test. Schirmer’s test scores significantly worsened at 30 and 90 days (p=0.008). No complications or adverse effects were observed. Conclusions: This study reinforces the use of autologous serum 20% as a successful treatment for severe dry eye disease resistant to conventional therapy. Autologous serum in 0.9% saline was not inferior to the methylcellulose formulation and is much more cost-effective.

Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19.

PurposeThe SARS‐CoV‐2 RNA has been detected in tears and conjunctival samples from infected individuals. Conjunctivitis is also reported in a small number of cases. We evaluated ocular symptoms and ocular tropism of SARS‐CoV‐2 in a group of patients with COVID‐19.MethodFifty‐six patients infected with SARS‐CoV‐2 were recruited as subjects. Relevant medical histories were obtained from the electronic medical record system. Ocular history and ocular symptoms data were obtained by communicating directly with the subjects. The Ocular Surface Disease Index (OSDI) and Salisbury Eye Evaluation Questionnaire (SEEQ) were used to assess the anterior ocular surface condition before and after the onset of disease.ResultsPatients classified as severe COVID‐19 cases were more likely to have hypertension compared to mild cases (p = 0.035). Of the 56 subjects, thirteen patients (23%) were infected in Wuhan, 32 patients (57%) were community‐infected, 10 patients (18%) were unknown origin, 1 (2%) was a physician likely infected by a confirmed patient. Three patients wore face mask with precaution when contacting the confirmed patients. Fifteen (27%) had aggravated ocular symptoms, of which 6 (11%) had prodromal ocular symptoms before disease onset. The differences in mean scores of OSDI questionnaire and SEEQ between before and after onset of COVID‐19 were all significant (p < 0.05 for both).ConclusionsOcular symptoms are relatively common in COVID‐19 disease and may appear just before the onset of respiratory symptoms. Our data provided the anecdotal evidences of transmission of SARS‐CoV‐2 via ocular surface.

Evaluation of Reliability and Validity of Three Common Dry Eye Questionnaires in Chinese.

Purpose To investigate the psychometric properties of three commonly used dry eye questionnaires including McMonnies Questionnaire (MQ), the Ocular Surface Disease Index (OSDI), and the Salisbury Eye Evaluation Questionnaire (SEEQ) in Chinese. Methods This prospective cross-sectional study was conducted at the Eye Hospital of Wenzhou Medical University. Ninety-eight participants completed three questionnaires in a random order. Ophthalmic examinations including tear break-up time, corneal fluorescein staining score, and Schirmer I test were performed. Reliability, validity, and accuracy were assessed for three questionnaires. Results There were 35 mild-to-moderate dry eye patients, 14 severe dry eye patients, and 49 non-dry eye patients. The Cronbach α of MQ, OSDI, and SEEQ was 0.54, 0.74, and 0.76, respectively, and the intraclass correlation coefficients were 0.91, 0.90, and 0.94, respectively. There were significant differences (P < 0.05) in MQ and OSDI scores among different groups, but there were no statistically significant differences between the mild-to-moderate group and the severe group in terms of SEEQ scores. With cutoff values for abnormal MQ of 15, OSDI of 27.2, and SEED of 1, respectively, good dry eye diagnostic accuracies were obtained. Conclusions The three questionnaires showed fair accuracy in the diagnosis of dry eye. The cutoff values of OSDI changed when applied to Chinese people.

Retinal Thickness May Be a Cognitive Biomarker

Back to table of contents Previous article Next article Clinical and Research NewsFull AccessRetinal Thickness May Be a Cognitive BiomarkerNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:3 Aug 2018https://doi.org/10.1176/appi.pn.2018.8a6AbstractTwo longitudinal studies have provided some of the first evidence that people with thinner retinal nerve fibers have higher risks of future cognitive problems and dementia.While an old proverb posits that eyes are windows to the soul, eyes are more technically windows to the brain. The retina—the rear portion of the eye—is a direct extension of the optic nerve, which is a component of the central nervous system. The thickness of the retina’s outer layer of nerve fibers might indicate future risk of cognitive problems. That this region can be easily imaged with current tools suggests a possible biomarker for early detection of Alzheimer’s and other dementias.iStock/CreVis2Numerous studies over the past decades have suggested that declines in vision and memory, both common with age, may be linked. Most recently, a study published in June in JAMA Ophthalmology concluded that worsening vision and declining cognitive function appear to change over time together. Vision problems had a stronger influence on future memory problems than the other way around, though, suggesting vision loss might predict future cognitive loss. Can information within the eyes be used by researchers and clinicians to predict those most likely to experience cognitive decline? Two studies published in June in JAMA Neurology suggest the answer to this question may be yes. Both studies pointed to retinal thickness as a potential biomarker for future cognitive decline, including Alzheimer’s disease.Both studies involved the use of a tool known as optical coherence tomography (OCT), which is widely used by clinicians to diagnose eye disorders such as glaucoma or macular degeneration. OCT uses light energy to reconstruct a 3-D model of the inner eye (similar to how an ultrasound works). In one of the studies, researchers at Erasmus University in the Netherlands looked directly at retinal changes and dementia. They assessed data from the Rotterdam Study, a large population-level aging study that has been monitoring older adults in the Rotterdam suburb of Ommoord since 1990. The participants received periodic eye exams and cognitive exams, allowing for a prospective analysis.The investigators identified about 3,300 adults who had taken an OCT and were free of any eye diseases at baseline. Over about 4.5 years, 86 of these adults developed some clinical dementia, including 68 who developed Alzheimer’s disease. The investigators found that the adults who had thinner retinas at baseline—specifically the layer of nerve fibers where retina and optic nerve meet—were more likely to subsequently develop dementia. When participants were divided into four groups based on retinal thickness, for example, those in the lowest quartile were more than two and a half times as likely to develop dementia as those in the highest quartile.For the other study, researchers at University College London analyzed the retinal nerve layer thickness and changes in cognitive performance in a group of adults aged 40 to 69, irrespective of cognitive disease. As with the Dutch group, the investigators made use of data available from a large aging study known as UK Biobank. The researchers examined clinical data from over 30,000 individuals who were both given an OCT scan and took multiple cognitive tests to measure their memory, reaction time, and reasoning skills every three years.The U.K. investigators stratified the participants into five groups (quintiles) based on retinal thickness. They found that compared with participants in the highest retinal quintile at baseline, participants in the second and third quintiles were about 1.5 times as likely to perform worse on at least one cognitive test after three years. Participants in the lowest two quintiles were about twice as likely to perform worse on follow-up cognitive tests.“Our study strengthens the argument of an association between neurodegenerative processes that affect the brain and the eye and indicates that OCT measurement of the [retinal nerve fiber layer] is a potential noninvasive, relatively low-cost, and time-efficient screening test for early cognitive changes,” wrote lead author Paul Foster, Ph.D., and colleagues.“However, one must be careful in [OCT] interpretation so as to avoid an unnecessary psychological burden for people who may not ultimately experience cognitive decline,” the authors continued. “Further, attempting to risk-stratify people would be most appropriate if there is a viable treatment or preventative measure available. Additional research is required to define a possible role for these observations in health policies and to determine the relevance at an individual level.” ■“Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline” can be accessed here. “Association of Retinal Neurodegeneration on Optical Coherence Tomography With Dementia” is available here. “Longitudinal Associations Between Visual Impairment and Cognitive Functioning: The Salisbury Eye Evaluation Study” is located here. ISSUES NewArchived

Demographic Profile and Risk Factors for Dry Eye

Introduction: Dry eye is a disorder of the tear film which occurs due to tear deficiency or excessive tear evaporation. It causes damage to the interpalpebral ocular surface and is associated with a variety of symptoms reflecting ocular discomfort.Materials and Methods: This was a hospital-based retrospective descriptive study conducted to study the demography of dry eye patients and associated attributable risk factors for the disease. Every patient presenting with symptoms suggestive of dry eye was given a questionnaire, as per Salisbury Eye Evaluation Study and thorough ocular examination was done along with two tests for dry eye i.e Schirmer test I measuring less than 10mm and Tear film break up time measuring less than 10 sec. Final data analysis was done using statistical tool SPSS.Results: Demographic profile revealed a female preponderance in the patients with a ratio of 1.9:1. Amongst them, prevalence of premenopausal age was 53%. Dry eye was found to be more common in age group between 30 to 40 years (29%). The modifiable attributable risk factors were urban residence (67%), exposure to air condition and computer user (52%), indoor workers (59%), and environmental pollutants (60%).Conclusions: This study revealed the patients who presented with dry eye were mostly female of premenopausal age group, and exposed to modifiable risk factors which included residing at urban areas, indoor work, and exposure to environmental pollutants. Nepalese Medical Journal. vol.1, No. 1, 2018, page: 9-11

Incidence and risk factors of symptomatic dry eye disease in Asian Malays from the Singapore Malay Eye Study

PurposeTo evaluate the incidence of symptomatic dry eye disease (SDED) and associated risk factors in a well-characterized cohort of ethnic Malays in Singapore. MethodsWe included 1682 participants (mean age [SD]: 57 [10]years; 55.4% female) without SDED from the Singapore Malay Eye Study (SiMES), a population-based longitudinal study with baseline examination (SiMES-1) conducted between 2004 and 2006, and follow-up examination (SiMES-2) conducted between 2010 and 2013. SDED was considered to be present if a participant answered “often” or “all the time” to any of the six questions from the Salisbury Eye Evaluation Study dry eye questionnaire. Age-standardized incidence of SDED was calculated as the crude 6-year cumulative incidence standardized to Singapore's population census. Gender-stratified multivariable log-binomial regression models were utilized to determine the independent risk factors of incident SDED. ResultsAt the 6-year follow-up, 86 of 1682 participants had developed SDED, which was equivalent to an age-standardized 6-year incidence of 5.1% (95% CI 4.1–6.4%). There were no differences in the incidence of SDED between men and women (P = 0.9). Multivariable models revealed that presence of glaucoma and poorer self-rated health were independently associated with incident SDED in men (P = 0.003 and 0.03, respectively), while contact lens wear (P = 0.002), history of thyroid disease (P = 0.03), and having had cataract surgery (P = 0.02) were predictive of incident SDED in women. ConclusionOne in twenty adult Malays developed SDED over a 6-year period. Risk factors for incident SDED were different between men and women. Future studies and public health interventions should consider this gender-specific difference in risk factors.

Effects of Muller’s muscle-conjunctival resection for ptosis on ocular surface scores and dry eye symptoms

ABSTRACTThis article evaluates the effects of Muller’s muscle-conjunctival resection (MMCR) on ocular surface scores and dry eye symptoms. Forty-six patients were enrolled in the study. Eighteen underwent bilateral upper eyelid skin excision with MMCR and 28 underwent bilateral upper eyelid skin-only excision (control group). The Salisbury Eye Evaluation Questionnaire and an ocular surface evaluation protocol consisting of Schirmer’s test, tear break-up time (TBUT), fluorescein and rose bengal corneal staining were performed during the pre-operative consultation and on postoperative days 7, 30, and 90. Improvement in symptoms questionnaire scores from baseline was observed on postoperative day 90 in the blepharoplasty plus MMCR group. There was no change in questionnaire scores in patients who underwent blepharoplasty alone. No between-group difference in Schirmer’s test, TBUT, or fluorescein and rose bengal staining was found at any time point. In the blepharoplasty-only (control group), the fluorescein staining score was reduced on postoperative day 30 as compared to baseline, but not on day 90. In this sample, addition of MMCR to upper eyelid blepharoplasty did not worsen ocular surface scores or dry eye symptoms.

In vivo Confocal Microscopy Evaluation of Meibomian Gland Dysfunction in Dry Eye Patients with Different Symptoms.

Background:Dry eye patients suffer from all kinds of symptoms. Sometimes, the clinical signs evaluation does not disclose any obvious difference in routine examination; in vivo confocal microscopy (IVCM) is a powerful tool for ocular surface disease. This study aimed to clarify meibomian gland (MG) alterations in dry eye patients with different symptoms and to compare the findings using IVCM.Methods:A total of sixty patients were recruited, all subjected to Ocular Surface Disease Index (OSDI) and Salisbury Eye Evaluation Questionnaire (SEEQ), and questionnaires for the assessment of dry eye symptoms before clinical sign examinations were given to the patients. Finally, IVCM was applied to observe MG's structure. Statistical analysis was performed using the t-test, Mann-Whitney U-test and Spearman correlation analysis. The differences were statistically significant when P < 0.05.Results:In the severe symptom group, OSDI and SEEQ scores were significantly higher (P < 0.05) compared with the mild symptoms group. All other clinical sign examinations had no statistical difference in the two groups (P > 0.05). However, all the IVCM-observed data showed that patients with severe symptoms had more significant fibrosis in MG (acinar unit area 691.87 ± 182.01 μm2 for the severe, 992.17 ± 170.84 μm2 for the mild; P < 0.05) and severer decrease in the size of MG acinar units than those observed in patients with mild symptoms (MG acinar unit density [MGAUD] 70.08 ± 18.78 glands/mm2, MG acinar unit longest diameter [MGALD] 51.50 ± 15.51 μm, MG acinar unit shortest diameter [MGASD] 20.30 ± 11.85 μm for the severe, MGAUD 89.53 ± 39.88 glands/mm2, MGALD 81.57 ± 21.14 μm, MGASD 42.37 ± 14.55 μm for the mild; P < 0.05). Dry eye symptoms were negatively correlated with MG confocal microscopic parameters and positively correlated with conjunctival inflammatory cells and Langerhans cells (P < 0.05).Conclusions:IVCM application provides a strong support to differentiate dry eye patients with different symptoms: meibomian gland dysfunction (MGD) plays a pivotal role in dry eye aggravation, and using IVCM to observe MG fibrosis, changes in size and density of MG as well as status of inflammation cells can help not only correctly diagnose the type and severity of dry eye, but also possibly prognosticate in routine eye examination in the occurrence of MGD.

Comparing the Impact of Refractive and Nonrefractive Vision Loss on Functioning and Disability: The Salisbury Eye Evaluation

To compare the effects of uncorrected refractive error (URE) and nonrefractive visual impairment (VI) on performance and disability measures. Cross-sectional, population-based study. A total of 2469 individuals with binocular presenting visual acuity (PVA) of ≥ 20/80 who participated in the first round of the Salisbury Eye Evaluation study. The URE was defined as binocular PVA of ≤ 20/30, improving to >20/30 with subjective refraction. The VI was defined as post-refraction binocular best-corrected visual acuity (BCVA) of ≤ 20/30. The visual acuity decrement due to VI was calculated as the difference between BCVA and 20/30, whereas visual acuity due to URE was taken as the difference between PVA and BCVA. Multivariable regression analyses were used to assess the disability impact of (1) vision status (VI, URE, or normal vision) using the group with normal vision as reference and (2) a 1-line decrement in acuity due to VI or URE. Objective measures of visual function were obtained from timed performance of mobility and near vision tasks, self-reported driving cessation, and self-reported visual difficulty measured by the Activities of Daily Vision (ADV) scale. The ADV responses were analyzed using Rasch analysis to determine visual ability. Compared with individuals with normal vision, subjects with VI (n = 191) had significantly poorer objective and subjective visual functioning in all metrics examined (P < 0.05), whereas subjects with URE (n = 132) demonstrated slower walking speeds, slower near task performance, more frequent driving cessation, and lower ADV scores (P < 0.05), but did not demonstrate slower stair climbing or descent speed. For all functional metrics evaluated, the impact of VI was greater than the impact of URE. The impact of a 1-line VA decrement due to VI was associated with greater deficits in mobility measures and driving cessation when compared with a 1-line VA decrement due to URE. Visual impairment is associated with greater disability than URE across a wide variety of functional measures, even in analyses adjusting for the severity of vision loss. Refractive and nonrefractive vision loss should be distinguished in studies evaluating visual disability and be understood to have differing consequences.

Longitudinal relationships between visual acuity and severe depressive symptoms in older adults: the Salisbury Eye Evaluation study

Objectives: To assess the longitudinal relationship between visual acuity (VA) and depressive symptoms (DSs) among older adults.Methods: A population-based sample of 2520 white and black individuals aged 65–84 years in 1993--1995 was assessed at baseline and at two, six, and eight years later. Presenting and best-corrected VA was assessed using early treatment diabetic retinopathy study chart. DSs were assessed using the severe depression subscale of General Health Questionnaire 28. Latent growth curve models estimated VA and DS trajectories and age-adjusted associations between trajectories.Results: Best-corrected logMAR VA worsened over time (slope = 0.026, intercept = 0.013, both p < 0.001). No change in DS over time was observed (slope = −0.001, p = 0.762; intercept = 1.180, p < 0.001). However, a small change in DS was observed in participants who completed all rounds (slope = 0.005, p = 0.015). Baseline VA levels correlated with baseline DS levels (r = 0.14, p < 0.001). Baseline DS was associated with best-corrected VA change (r = 0.17, p = 0.01). Baseline best-corrected VA was not associated with DS change (r = 0.017, p = 0.8). Best-corrected VA change was not significantly associated with DS change (r = −0.03, p = 0.7).Discussion: DSs are significantly associated with VA cross-sectionally, and persons with higher baseline DS scores were more likely to experience worsening VA over time. The complex relationship between visual impairment and DS suggests the need for a continued effort to detect and treat both visual decline and severe DSs in a growing elderly population.

Dry Eye Disease following Refractive Surgery: A 12-Month Follow-Up of SMILE versus FS-LASIK in High Myopia

Purpose. To compare dry eye disease following SMILE versus FS-LASIK. Design. Prospective, nonrandomised, observational study. Patients. 90 patients undergoing refractive surgery for myopia were included. 47 eyes underwent SMILE and 43 eyes underwent FS-LASIK. Methods. Evaluation of dry eye disease was conducted preoperatively and at 1, 3, 6, and 12 months postoperatively, using the Salisbury Eye Evaluation Questionnaire (SEEQ) and TBUT. Results. TBUT reduced following SMILE at 1 and 3 months (p < 0.001) and at 1, 3, and 6 months following FS-LASIK (p < 0.001). TBUT was greater following SMILE than FS-LASIK at 3, 6, and 12 months (p < 0.001, p < 0.001, and p = 0.009, resp.). SEEQ scores increased (greater symptoms) following SMILE at 1 month (p < 0.001) and 3 months (p = 0.003) and at 1, 3, and 6 months following FS-LASIK (p < 0.001). SMILE produced lower SEEQ scores (fewer symptoms) than FS-LASIK at 1, 3, and 6 months (p < 0.001). Conclusion. SMILE produces less dry eye disease than FS-LASIK at 6 months postoperatively but demonstrates similar degrees of dry eye disease at 12 months.

Longitudinal relationships among visual acuity, daily functional status, and mortality: the Salisbury Eye Evaluation Study.

Determination of the mechanisms by which visual loss increases mortality risk is important for developing interventional strategies. To evaluate the direct and indirect effects of loss of visual acuity (VA) on mortality risk through functional status changes among aging adults. Prospective longitudinal study of a population-based sample of 2520 noninstitutionalized adults aged 65 to 84 years from September 16, 1993, through July 26, 2003, in the greater Salisbury area of Maryland. Participants underwent reassessment 2, 6, and 8 years after baseline. Mortality status was ascertained from linkage with the National Death Index through 2009. Results of VA testing and self-reported functional status based on activities of daily living (ADL) and instrumental ADL (IADL). Mortality. Worse VA levels at baseline were associated with an increased the risk for mortality (hazard ratio [HR], 1.16 [95% CI, 1.04-1.28]; P < .01) through their effect on lower IADL levels at baseline. Declines in VA over time were associated with increased mortality risk (HR, 1.78 [95% CI, 1.27-2.51]; P < .001) by way of decreasing IADL levels over time. Participants experiencing the mean linear decline in VA of 1 letter on the Early Treatment Diabetic Retinopathy Study acuity chart per year are expected to have a 16% increase in mortality risk during the 8-year study exclusively through associated declines in IADL levels. In this longitudinal study of older adults, VA loss adversely affected IADL levels, which subsequently increased the risk for mortality. Prevention of disabling ocular conditions, treatment of correctable visual impairment, and interventions designed to prevent the effect of visual impairment on IADL declines may all reduce mortality risk in aging adults.

Does walking speed mediate the association between visual impairment and self-report of mobility disability? The Salisbury Eye Evaluation Study.

To determine whether performance speeds mediate the association between visual impairment and self-reported mobility disability over an 8-year period. Longitudinal analysis. Salisbury, Maryland. Salisbury Eye Evaluation Study participants aged 65 and older (N=2,520). Visual impairment was defined as best-corrected visual acuity worse than 20/40 in the better-seeing eye or visual field less than 20°. Self-reported mobility disability on three tasks was assessed: walking up stairs, walking down stairs, and walking 150 feet. Performance speed on three similar tasks was measured: walking up steps (steps/s), walking down steps (steps/s), and walking 4 m (m/s). For each year of observation, the odds of reporting mobility disability was significantly greater for participants who were visually impaired (VI) than for those who were not (NVI) (odds ratio (OR) difficulty walking up steps=1.58, 95% confidence interval (CI)=1.32-1.89; OR difficulty walking down steps=1.90, 95% CI=1.59-2.28; OR difficulty walking 150 feet=2.11, 95% CI=1.77-2.51). Once performance speed on a similar mobility task was included in the models, VI participants were no longer more likely to report mobility disability than those who were NVI (OR difficulty walking up steps=0.84, 95% CI=0.65-1.11; OR difficulty walking down steps=0.96, 95% CI=0.74-1.24; OR difficulty walking 150 feet=1.22, 95% CI=0.98-1.50). Slower performance speed in VI individuals largely accounted for the difference in the odds of reporting mobility disability, suggesting that VI older adults walk slower and are therefore more likely to report mobility disability than those who are NVI. Improving mobility performance in older adults with visual impairment may minimize the perception of mobility disability.

Does Visual Impairment Affect Mobility Over Time? The Salisbury Eye Evaluation Study

To determine if the odds of mobility disability increases at a different rate among visually impaired (VI) as compared with nonvisually impaired (NVI) over an 8-year period. A total of 2520 Salisbury Eye Evaluation Study participants were followed 2, 6, and 8 years after baseline. VI was defined as best-corrected visual acuity worse than 20/40, or visual field of approximately less than 20°. Self-reported difficulty with three tasks was assessed at each visit: walking up 10 steps, walking down 10 steps, and walking 150 feet. Generalized estimating equation models included a 6-year spline, and explored differences in mobility difficulty trajectories by including an interaction between VI status and the spline terms. Odds ratios (OR) and 95% confidence intervals (CI) compared mobility difficulty for each task by VI status. At baseline, the VI were significantly more likely to report difficulty mobility tasks than the NVI (OR(difficultywalkingup10steps) = 1.37, CI: 1.02-1.80; OR(difficultywalkingdown10steps) = 1.55, CI: 1.16-2.08; OR(difficultywalking150feet) = 1.50, CI: 1.10-2.04). The trajectory of mobility disability did not differ by VI status from baseline to the 6-year visit. However, the difference between the VI and NVI declined at the 8-year visit, which may be due to loss of VI participants at risk of developing mobility difficulty. The VI were more likely to report mobility disability than the NVI, but the trajectory of mobility disability was not steeper among the VI as compared to the NVI over the study period.

Worldwide reduction in blindness: making progress?

Worldwide reduction in blindness: making progress?

A Longitudinal Study of the Association Between Visual Impairment and Mobility Performance in Older Adults: The Salisbury Eye Evaluation Study

Few longitudinal studies have examined how visual impairment affects mobility as people age. Data from the Salisbury Eye Evaluation Study, a population-based sample of 2,520 adults aged 65 years and older, were used to investigate the longitudinal association between visual impairment and mobility. Baseline, 2-year, 6-year, and 8-year visits occurred between 1993 and 2001. Mobility was assessed by measuring speeds on the following 3 tasks: walking up 7 steps, walking down 7 steps, and walking 4 m. Random-effects linear regression was used to model factors affecting speed. For each year of observation, speeds declined, and the visually impaired had significantly slower speeds than the non--visually impaired on all 3 tests after accounting for other covariates (βwalking up steps = -0.08 steps/second, 95% confidence interval (CI): -0.10, -0.06; βwalking down steps = -0.11 steps/second, 95% CI: -0.14, -0.08; and βwalking 4 m = -0.08 m/second, 95% CI: -0.10, -0.06). However, the interaction between years since baseline and visual impairment status was not significant, indicating that mobility speeds declined at a similar rate in the visually impaired and the non--visually impaired. These results suggest that the impact of visual impairment on speed is significant but does not change as people age.

Impact of dry eye on reading in a population-based sample of the elderly: the Salisbury Eye Evaluation

Background/aimsPeople with dry eye often complain of difficulty reading, but this perceived deficit has not been appropriately quantified. The purpose of this study is to determine if dry eye is...

Associations Between Self-Rated Vision Score, Vision Tests, and Self-Reported Visual Function in the Salisbury Eye Evaluation Study

We attempt to understand the determinants of self-rated vision status by examining associations with vision tests, self-reported visual function, demographic, and health-status characteristics. Participants included 2467 individuals, aged 65 to 84 years, in a longitudinal, population-based cohort study. Participants rated their vision status from 0 to 10. Visual acuity, contrast sensitivity, stereoacuity, and visual fields were assessed. The Activities of Daily Vision Scale (ADVS) questionnaire was administered. Multivariate ordinal and multinomial logistic-regression models examined the association of demographic, health-status characteristics, vision tests, and ADVS subscales with self-rated vision status score. Odds ratios described the association of these characteristics with reporting better vision status. Better visual acuity, contrast sensitivity, stereoacuity, and visual fields were associated with increased odds of reporting better vision status. Among the vision tests, a 2-line increase in visual acuity was most likely to result in an individual reporting better vision status (odds ratio, 1.49; 95% confidence interval [CI], 1.30-1.70). A 5-point increase in the near vision and far vision ADVS subscale scores was associated with increased odds of reporting good versus poor vision status. A 5-point increase in the near vision subscale was most likely to result in an individual reporting good versus poor vision status (odds ratio, 1.38; 95% CI, 1.28-1.50). Self-rated vision status is a multidimensional measure. Near-vision visual function, visual acuity, and contrast sensitivity are important determinants of self-rated vision status in an elderly population. This understanding may improve the ability of eye care providers to maximize self-rated vision status among their patients.

The Relationship between Better-Eye and Integrated Visual Field Mean Deviation and Visual Disability

To determine the extent of difference between better-eye visual field (VF) mean deviation (MD) and integrated VF (IVF) MD among Salisbury Eye Evaluation (SEE) subjects and a larger group of glaucoma clinic subjects and to assess how those measures relate to objective and subjective measures of ability/performance in SEE subjects. Retrospective analysis of population- and clinic-based samples of adults. A total of 490 SEE and 7053 glaucoma clinic subjects with VF loss (MD ≤-3 decibels [dB] in at least 1 eye). Visual field testing was performed in each eye, and IVF MD was calculated. Differences between better-eye and IVF MD were calculated for SEE and clinic-based subjects. In SEE subjects with VF loss, models were constructed to compare the relative impact of better-eye and IVF MD on driving habits, mobility, self-reported vision-related function, and reading speed. Difference between better-eye and IVF MD and relationship of better-eye and IVF MD with performance measures. The median difference between better-eye and IVF MD was 0.41 dB (interquartile range [IQR], -0.21 to 1.04 dB) and 0.72 dB (IQR, 0.04-1.45 dB) for SEE subjects and clinic-based patients with glaucoma, respectively, with differences of ≥ 2 dB between the 2 MDs observed in 9% and 18% of the groups, respectively. Among SEE subjects with VF loss, both MDs demonstrated similar associations with multiple ability and performance metrics as judged by the presence/absence of a statistically significant association between the MD and the metric, the magnitude of observed associations (odds ratios, rate ratios, or regression coefficients associated with 5-dB decrements in MD), and the extent of variability in the metric explained by the model (R(2)). Similar associations of similar magnitude also were noted for the subgroup of subjects with glaucoma and subjects in whom better-eye and IVF MD differed by ≥ 2 dB. The IVF MD rarely differs from better-eye MD, and similar associations between VF loss and visual disability are obtained using either MD. Unlike better-eye MD, IVF measurements require extra software/calculation. As such, information from studies using better-eye MD can be more easily integrated into clinical decision-making, making better-eye MD a robust and meaningful method for reporting VF loss severity.